Table 2.

Association of ADNI-mem, tau (flortaucipir) and Aβ (florbetapir) uptake for CSF progranulin baseline concentrations and rates of change over time (slope)

Variable	Entire cohort (n = 1001)		A-/TN- (n = 246)		A + /TN- (n = 166)		A-/TN + (n = 182)		A + /TN + (n = 407)
	β	P-value	β	P-value	β	P-value	β	P-value	β	P-value
ADNI-mem
CSF progranulin	− 0.104	< 0.001	− 0.152	0.013	− 0.141	0.06	0.006	0.933	− 0.103	0.041
CSF-progranulin slope	− 0.011	0.823	0.028	0.775	− 0.024	0.847	− 0.14	0.194	− 0.023	0.778
Aβ-PET
CSF progranulin	− 0.015	0.656	− 0.004	0.959	− 0.046	0.618	− 0.159	0.059	− 0.027	0.674
CSF-progranulin slope	0.092	0.089	0.08	0.514	0.022	0.867	0.306	0.015	0.109	0.317
Tau-PET
CSF progranulin	− 0.02	0.351	− 0.109	0.465	− 0.038	0.827	− 0.167	0.315	− 0.245	0.231
CSF-progranulin slope	− 0.017	0.864	− 0.17	0.364	0.128	0.541	− 0.03	0.904	0.443	0.321
Aβ-PET rate of change
CSF progranulin	− 0.054	0.26	0.034	0.706	− 0.196	0.118	− 0.205	0.053	− 0.097	0.298
CSF-progranulin slope	− 0.022	0.728	− 0.005	0.97	0.048	0.767	0.311	0.023	− 0.186	0.09
Tau-PET rate of change
CSF progranulin	− 0.207	0.016	− 0.262	0.092	− 0.052	0.8	− 0.264	0.145	− 0.269	0.246
CSF-progranulin slope	0.138	0.238	0.29	0.136	− 0.045	0.855	0.146	0.213	− 0.248	0.312

Analyses adjusted for age, sex and APOE e4/PET scan. Baseline cognition was included in the model when predicting ADNI-mem at follow-up

Aβ amyloid β, A + /− Amyloid-β positive/negative, ADNI Alzheimer’s Disease Neuroimaging Initiative, ATN Aβ deposition, tau pathology and neurodegeneration, β beta, β standardized beta, TN + /− Tau/Neurodegeneration positive/negative